Our results furthermore confirm our recently proposed K-Ras-directed HIF1α and Gal3-dependent mechanism of action of Hsp90 inhibitors, suggesting that KRAS mutant cancers should be considered for the evaluation of Hsp90 inhibitors in the future. The gene discussed is KRAS; the disease is cancer.